Genomic R&D Investment Should Track Functional Data - Novartis' Karabelas
Executive Summary
Genomics-based research & development programs that do not concentrate on data tied to functional information risk squandering resources, Novartis Worldwide Pharmaceutical Division CEO Argeris Karabelas told the PDA International Congress Feb. 14 in Basel, Switzerland.